Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Silicon phthalocyanine 158 (Pc 158) is a second-generation photosensitizer used in photodynamic therapy (PDT) that primarily targets the mitochondrial and endoplasmic reticulum (ER) compartments of cells. Upon activation by specific wavelengths of light, Pc 158 generates reactive oxygen species, particularly singlet oxygen, which causes localized oxidative damage to its target environment. The primary molecular target within this environment is the anti-apoptotic protein Bcl-2, which is degraded or inactivated, leading to the rapid induction of apoptosis via the intrinsic pathway. Pc 158 is highly hydrophobic and localizes preferentially in lipid-rich organelle membranes, making it effective against various cancer cell lines by disrupting mitochondrial integrity and triggering cell death signals.
Photosensitization leading to singlet oxygen production and subsequent Bcl-2 degradation and mitochondrial dysfunction
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Silicon phthalocyanine 158 (Pc 158).